Equibles does not estimate personal net worth.
Get an email with a short summary when Coherus Oncology, Inc. publishes a filing, an earnings call transcript or a press release.
Get CHRS alertsDennis Lanfear is recorded as CEO at Coherus Oncology, Inc. (CHRS). The newest filing on record that lists Dennis Lanfear as CEO at Coherus Oncology, Inc. (CHRS) is dated April 20, 2026. The proxy statement of Coherus Oncology, Inc. reports total compensation of $5,361,707 for Dennis Lanfear in fiscal 2019, including a base salary of $750,737. Dennis Lanfear has spoken on 24 earnings calls and 2 other investor events across 1 company, most recently for Coherus Oncology, Inc. on September 16, 2026. Coherus Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Coherus Oncology, Inc. includes Bryan McMichael (CFO and Chief Accounting Officer), Alan C. Mendelson (Board Member), Charles Newton (Board Member) and 6 others.
“Thank you very much, Matt, and thank you for the opportunity to speak at your conference this afternoon. So Coheros is about the business of overcoming immune resistance in cancer, and we do this, I think, with three of our products, which are very interesting.”
“Coheris is chairman and chief executive officer. To my left is Dr. Raj Dias, the company's chief medical officer. Let me first apprise you of the forward-looking statements and direct you to the company's regulatory filings for further details with respect to the products, Tagmonketog, Casdozo Ketog, and Lactorsi.”
“Well, thank you, Carrie, and thank you all for joining us this afternoon on our Q1-2026 quarterly call. Let me first give you a quick flyby with the company's strategy to make sure we level set everyone, including our new investors.”
“Thank you, Carrie, and thank you all for joining us today on our Q4 2025 call and our 2025 annual summary to investors. This was a year in which we completed our strategic transformation to an innovative oncology company focused on overcoming immune resistance in cancer.”
“Thank you, Carrie, and good afternoon, everyone, and welcome to our Q3 2025 earnings call. As we get started, let me first welcome Arvind Sood to Coherus Oncology, our newly appointed Chief Strategy and Corporate Affairs Officer.”
Start not stated–present
Last confirmed April 20, 2026
Biotechnology · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Coherus Oncology, Inc. (CHRS) | President, Chief Executive Office and Chairman of the Board of Directors | $750,737 | $5,361,707 |
